Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.
Dilek Çağlayan, Melek Çağlayan
✦ AI-curated · Sources linked
Case in brief
A 59-year-old woman with end-stage kidney disease receiving hemodialysis three times weekly was diagnosed with hormone receptor-positive, HER2-negative metastatic breast cancer involving bone. She received ribociclib alongside letrozole and denosumab. Ribociclib was reduced because of hematological toxicity. PET/CT showed 50% regression of the primary tumour and partial reduction in metabolic activity of the bone metastases. The report describes ribociclib as safely administered with treatment response over nine months.
What made this case unusual
The case describes ribociclib use in a patient receiving chronic hemodialysis, a setting in which the authors report limited clinical experience.
Diagnostic / clinical pearl
In this reported patient on chronic hemodialysis, ribociclib was administered with dose reduction for hematological toxicity and was associated with radiographic response; the case supports careful, individualized use rather than establishing general safety.